The presentation will be jointly delivered by Thomas S. Paterson, Chief Scientific Officer of Entelos, and Robert J. Dinerstein
, M.D., Ph.D., Senior Research Scientist of Aventis Pharma.
Paterson and Dinerstein
will be discussing the asthma PhysioLab, the principles and components of its design, and why the use of modeling and simulation systems are a critical next step for the drug industry.
...Dr. Robert Dinerstein
is a senior research scientist in the Respiratory Diseases Group at Aventis Pharma.Prior to joining Hoechst Marion Roussel, a predecessor of the Aventis organization, in 1985, Dr. Dinerstein
held the position of assistant professor at the University of Chicago Department of Pharmacological and Physiological Sciences.He
Ph.D. in Organic Chemistry at the University of Oregon, and earned his
M.D. at the University of Chicago.
Entelos, Inc. (http : //www.entelos.com), headquartered in Menlo Park, California, is the commercial leader in virtual research and development systems for the pharmaceutical and biotechnology communities.The company provides predictive biological modeling and disease-simulation systems for drug discovery, development, and commercialization.The company's premier products, PhysioLabs, are rigorous quantitative models of human physiology that provide researchers and clinicians with a new system for testing hypotheses, managing scientific and clinical data, and conducting virtual experiments.Entelos offers PhysioLab subscriptions, a range of professional services, and development partnerships.Entelos Obesity PhysioLab and Entelos Asthma PhysioLab are available today.A diabetes PhysioLab and an adipocytes CytoLab are scheduled for completion this year.